OpenEvidence

OpenEvidence is a US-based artificial intelligence (AI) company that provides a medical search engine designed to assist physicians in making evidence-based clinical decisions. Founded in 2022 by Daniel J. Nadler, a Harvard Ph.D. and former founder of Kensho, and Zachary Ziegler, a Harvard machine learning researcher, the company aims to address the challenge of keeping up with the rapidly growing volume of medical research. OpenEvidence's platform uses AI to simplify and summarise complex research, offering doctors accurate, up-to-date insights in seconds.
 

The company's AI model has achieved remarkable success, scoring 90% on the United States Medical Licensing Examination (USMLE) in 2023 and later reaching a perfect score in 2025. OpenEvidence partners with renowned organisations like the American Medical Association and The New England Journal of Medicine to enhance its offerings. As of mid-2025, over 430,000 U.S. physicians, or 40% of the total physician population, use the platform, which supports over 8.5 million consultations per month.
 

In terms of funding, OpenEvidence raised $75 million in a Series A round in February 2025, followed by a $210 million Series B round in July 2025, co-led by Google Ventures and Kleiner Perkins, which valued the company at $3.5 billion. OpenEvidence's business model offers free access to verified physicians, generating revenue through advertising.

The history of OpenEvidence begins with its founding in late 2021 (commonly recorded as 2022) by Daniel J. Nadler and Zachary Ziegler. Nadler had previously founded Kensho Technologies (acquired by S&P Global in 2018) and, together with Ziegler, launched OpenEvidence to tackle the problem of information overload in medicine. 
 

In its early stage, OpenEvidence participated in the Mayo Clinic Platform Accelerate programme which provided support and an environment to refine its vision of a medical?search engine powered by artificial intelligence that could aggregate and synthesise peer?reviewed research into formats clinicians could use. 

In July 2023, the company announced that its AI model had become the first to score over 90% on the United States Medical Licensing Examination (USMLE), demonstrating early proof?of?concept for its ability to interpret and apply medical literature.

In February 2025, OpenEvidence secured a Series A funding round of approximately US$75?million led by Sequoia Capital, with the company valued at about US$1?billion. Around the same time, OpenEvidence signed a multi?year content agreement with the NEJM Group (publisher of The New England Journal of Medicine), granting access to full?text content and multimedia from 1990 onwards to improve the platform’s evidence base.
 

In June 2025, OpenEvidence entered into a content agreement with the JAMA Network (publisher of the Journal of the American Medical Association and 11 specialty journals), enabling full?text and multimedia content from across multiple specialties to feed its platform. 
 

In July 2025, the company announced a Series B funding round of US$210?million co?led by GV (formerly Google Ventures) and Kleiner Perkins, which valued the company at approximately US$3.5?billion. This funding took total capital raised to over US$300?million. 
 

Concurrent with that funding announcement, OpenEvidence introduced a new feature called DeepConsult—a specialised AI?agent purpose?built for physicians to synthesise cross?study findings and support clinical decisions more deeply. 
 

As of mid?2025, OpenEvidence was in use by over 430,000 registered U.S. physicians (approximately 40?% of U.S. physicians), supporting more than 8.5?million consultations per month, and employed across over 10,000 hospitals and medical centres.
 

Thus, today OpenEvidence stands as a leading AI?driven platform for clinical decision support, operating freely for verified physicians, supported by strategic content partnerships and major venture funding, and aiming to further bridge the gap between medical research and bedside care.

OpenEvidence’s mission is to empower physicians with fast, evidence-based insights that simplify clinical decision-making. By leveraging advanced artificial intelligence, OpenEvidence helps doctors access, analyse, and apply the latest medical research in seconds. The platform aims to improve patient care by providing accurate, up-to-date information, enabling doctors to make informed decisions faster. With a focus on accessibility, OpenEvidence is committed to supporting healthcare professionals worldwide in navigating the growing volume of medical literature, enhancing productivity and improving outcomes for patients.

OpenEvidence envisions a future where every healthcare professional has seamless access to the latest evidence, helping them provide the best care possible. The company strives to transform the way medical knowledge is accessed, interpreted, and applied, using AI to connect doctors with the most relevant research in real-time. By simplifying complex information, OpenEvidence aims to empower physicians and improve patient outcomes on a global scale. The platform is designed to continuously evolve with advancements in AI, ensuring healthcare professionals have the tools they need to keep up with the ever-growing medical field.

OpenEvidence has earned significant recognition in the healthcare and AI sectors. In 2025, Daniel Nadler, the company’s co-founder, was named to the TIME100 Health list, recognising his contribution to global health through AI innovation. The platform’s AI model achieved a perfect score on the United States Medical Licensing Examination (USMLE), showcasing its capabilities in medical knowledge interpretation. OpenEvidence has also partnered with leading institutions like the American Medical Association and The New England Journal of Medicine, further solidifying its reputation as a trusted tool for healthcare professionals.

OpenEvidence offers a comprehensive platform that aids healthcare professionals in making quick, evidence-based clinical decisions. By using advanced artificial intelligence (AI), the company provides access to a wealth of medical research, helping physicians easily navigate and understand complex medical literature. Here are the core products and services offered by OpenEvidence:

1. AI-Powered Search Engine
The main product of OpenEvidence is its AI-powered medical search engine, designed to simplify the process of finding and applying research. The platform aggregates and organises peer-reviewed medical literature from reputable sources such as The New England Journal of Medicine, The Journal of the American Medical Association, and other clinical journals. By using advanced AI algorithms, OpenEvidence quickly provides physicians with up-to-date, relevant research tailored to their clinical needs. This helps doctors stay informed without needing to sift through thousands of articles manually.
 

2. DeepConsult
One of the key features introduced in 2025 is DeepConsult. This advanced AI tool is designed to synthesise findings from multiple studies, offering detailed and actionable insights for doctors. DeepConsult analyses clinical data, cross-references studies, and helps doctors reach well-informed conclusions more quickly. The tool makes it easier to understand complex research by presenting summarised insights in a clear and easily digestible format. DeepConsult has the ability to support more accurate clinical decision-making by ensuring physicians have a broader understanding of available medical evidence.
 

3. Evidence-based Insights
OpenEvidence's platform provides evidence-based insights directly to healthcare professionals. The platform analyses millions of research papers and clinical trials, presenting findings in an accessible manner. By doing so, OpenEvidence ensures that physicians can make quicker, better decisions during consultations. The service focuses on helping doctors apply the most recent medical findings to real-world scenarios, improving the overall quality of care provided to patients.
 

4. Clinical Decision Support (CDS)
OpenEvidence's platform is a valuable tool for clinical decision support. With its ability to analyse large volumes of medical research, it provides real-time guidance to physicians, helping them make informed decisions during patient care. Whether for diagnosis, treatment options, or understanding the latest medical innovations, OpenEvidence supports doctors in their day-to-day decision-making processes. The platform’s CDS tools are built to ensure that the information is easy to understand and directly relevant to the patient’s condition, ultimately improving outcomes and reducing errors.
 

5. Physician Access
OpenEvidence offers its platform to verified physicians free of charge. By providing no-cost access, OpenEvidence ensures that medical professionals at all levels can benefit from the resources available on the platform. This is particularly valuable for physicians who work in busy environments and cannot afford the time to search for relevant research manually. The platform’s simplicity and ease of use make it a critical tool for doctors, allowing them to focus on patient care rather than time-consuming research.

6. Partnerships with Medical Institutions
OpenEvidence has established strong partnerships with prestigious medical institutions, including the American Medical Association and The New England Journal of Medicine. These collaborations help ensure that the platform remains at the forefront of medical research, providing physicians with the most reliable and current evidence. Such partnerships allow OpenEvidence to offer an expanded range of resources and increase its credibility in the healthcare industry.
 

7. Data Security and Privacy
OpenEvidence ensures that all data shared on its platform is secure. It adheres to stringent data protection standards to ensure compliance with privacy laws and regulations. This is especially important in the medical field, where patient confidentiality is paramount. By maintaining high standards of security, OpenEvidence provides peace of mind to both healthcare professionals and patients alike.